| Luai Fadi Madanat, MD | |
|
3601 W 13 Mile Road, Royal Oak, MI 48073 | |
| (248) 898-4163 | |
| (248) 898-4163 |
| Full Name | Luai Fadi Madanat |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 3601 W 13 Mile Road, Royal Oak, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255956389 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 4351046277 (Michigan) | Secondary |
| 207R00000X | Internal Medicine | 4351046277 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Luai Fadi Madanat, MD 3601 W 13 Mile Road, Royal Oak, MI 48073 Ph: (248) 551-3000 | Luai Fadi Madanat, MD 3601 W 13 Mile Road, Royal Oak, MI 48073 Ph: (248) 898-4163 |
News Archive
Researchers used a new imaging technique to take high quality color photographs of the clinical stages of ocular inflammation in mice, and the technology could help in the monitoring and treatment of diseases of the eye that may cause blindness.
In findings that could have implications for autoimmune disorders and drug-resistant bacterial infections, researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key protein involved in the appropriate shut-down of inflammation following an immune response to invading pathogens.
VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.
Acute dendritic leukaemia is a rare type of leukaemia, but one with the worst prognosis-the average patient survival rate is just 12-14 months-that is difficult to treat. Juan Cruz Cigudosa's team, from the Spanish National Cancer Research Centre's Molecular Cytogenetics Group, has for the first time sequenced the exome -the coding, or protein-generating, regions of the genome- of dendritic cell leukaemia.
› Verified 8 days ago
Nicole Marijanovich, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-7999 Fax: 248-898-0580 | |
Vinayata Manuballa Kareti, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 661-948-0803 | |
Filip Ionescu, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-551-3000 | |
Christopher Carpenter, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3535 W 13 Mile Rd Ste 605, Royal Oak, MI 48073 Phone: 248-551-0495 | |
Dr. Matthew Burns Cotant, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3577 W 13 Mile Rd, Suite 404, Royal Oak, MI 48073 Phone: 248-551-6900 Fax: 248-551-6909 | |
Geoffrey Prysak, MD, MPH Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-7999 | |
Taylor Schoenheit, Internal Medicine Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-6509 |